Page last updated: 2024-12-07

plicatic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

plicatic acid: major non-volatile fraction in red cedar dust; identified by inhalation challenge as allergen; RN given refers to (1S-(1 alpha,2 alpha,3 beta))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID104836
CHEBI ID8272
SCHEMBL ID452275
MeSH IDM0053220

Synonyms (19)

Synonym
dust, western red cedar
1-(3,4-dihydroxy-5-methoxyphenyl)-1,2,3,4-tetrahydro-2,3,7-trihydroxy-3-(hydroxymethyl)-6-methoxy-2-naphthalenecarboxylic acid (1s-(1alpha,2alpha,3beta))-
nsc 72234
2-naphthalenecarboxylic acid, 1-(3,4-dihydroxy-5-methoxyphenyl)-1,2,3,4-tetrahydro-2,3,7-trihydroxy-3-(hydroxymethyl)-6-methoxy-, (1s,2s,3r)-
ai3-28401
brn 2712741
(1s-(1alpha,2alpha,3beta))-1-(3,4-dihydroxy-5-methoxyphenyl)-1,2,3,4-tetrahydro-2,3,7-trihydroxy-3-(hydroxymethyl)-6-methoxy-2-naphthalene carboxylic acid
16462-65-0
plicatic acid
(1s,2s,3r)-1-(3,4-dihydroxy-5-methoxyphenyl)-2,3,7-trihydroxy-3-(hydroxymethyl)-6-methoxy-1,4-dihydronaphthalene-2-carboxylic acid
4-10-00-02434 (beilstein handbook reference)
g3vf11qd86 ,
unii-g3vf11qd86
SCHEMBL452275
(1s,2s,3r)-1-(3,4-dihydroxy-5-methoxyphenyl)-1,2,3,4-tetrahydro-2,3,7-trihydroxy-3-(hydroxymethyl)-6-methoxy-2-naphthalenecarboxylic acid
plicatic acid [mi]
CHEBI:8272
DTXSID40894748
Q7204956

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" They were challenged with a maximum dosage of 80 mg of red cedar dust and spruce dust (control) with a rotahaler on separate days in a single blinded manner."( New method for an occupational dust challenge test.
Chan-Yeung, M; Chen, H; Lin, FJ, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
lignanAny phenylpropanoid derived from phenylalanine via dimerization of substituted cinnamic alcohols, known as monolignols, to a dibenzylbutane skeleton. Note that while individual members of the class have names ending ...lignane, ...lignene, ...lignadiene, etc., the class names lignan, neolignan, etc., do not end with an "e".
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (50.00)18.7374
1990's13 (34.21)18.2507
2000's2 (5.26)29.6817
2010's4 (10.53)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.16 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.50%)5.53%
Reviews2 (5.00%)6.00%
Case Studies4 (10.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (82.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]